(Source: European Parliament)
At Wednesday’s debate on ensuring global access to shots, there was a lack of consensus among MEPs on a temporary waiver of patent rights for COVID-19 vaccines.
A number of speakers called on the Commission to support a waiver of the intellectual property rights (IPR) for COVID-19 vaccines as an essential element in accelerating the rollout of shots to low and middle income countries.
In turn, many MEPs argued a patent waiver is a “false good idea” that would not speed up the provision of vaccines and would harm innovation. Instead, they argued the Commission should push …